MAP2K7 and melanoma: Some trials have investigated efficacy and safety of triple therapy combinations (BRAF/MEK inhibition in combination with anti-PD-1/PD-L1) in BRAF-mutant melanoma but have in general shown high rates of TRAEs [96,97].